Sirohi Bhawna, Smith Katy
Addenbrookes Hospital, Hills Road, Cambridge, UK.
Expert Rev Anticancer Ther. 2008 Oct;8(10):1559-68. doi: 10.1586/14737140.8.10.1559.
The monoclonal antibody bevacizumab, targeted against the angiogenesis factor VEGF has clinical activity against several common cancers. In metastatic breast cancer it improves response rate and time to progression in combination with paclitaxel/docetaxel compared with paclitaxel/docetaxel alone; the drug is currently being investigated in other combination regimens and as adjuvant and neoadjuvant therapy in early breast cancer. It is generally well tolerated. Side effects, including hypertension, proteinuria, thrombosis and bleeding, are uncommon and usually managed easily. Based on the clinical efficacy of bevacizumab, other small-molecule oral antiangiogenesis agents are now also under development.
针对血管生成因子VEGF的单克隆抗体贝伐单抗对几种常见癌症具有临床活性。在转移性乳腺癌中，与单独使用紫杉醇/多西他赛相比，它与紫杉醇/多西他赛联合使用可提高缓解率和疾病进展时间；该药物目前正在其他联合治疗方案中进行研究，并作为早期乳腺癌的辅助和新辅助治疗。它通常耐受性良好。副作用包括高血压、蛋白尿、血栓形成和出血，并不常见，通常也易于处理。基于贝伐单抗的临床疗效，其他小分子口服抗血管生成药物目前也在研发中。
